Compare Phillips 66 (PSX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Sanofi SA — how do they compare? Phillips 66 trades at $211.8 (market cap $85.11B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| PSX | SNY | |
|---|---|---|
Market Cap | $85.11B | $104.85B |
Sector | Energy | Health |
52-Week High | $212.27 | $52.34 |
52-Week Low | $118.37 | $41.33 |
Enterprise Value | $107.08B | $121.38B |
Dividend Yield | 2.39% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $212.27, up 2.62% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026's positive surprise, highlight operational strength amid volatile energy markets. The stock benefits from robust refining margins and disciplined capital returns, including a $1.27 quarterly dividend. Valuation metrics like a P/E of 20.63 and P/S of 0.63 suggest relative affordability compared to sector peers.
Outlook remains positive due to tight fuel markets and efficient refining operations, though risks include oil price volatility and declining revenue trends. With 57% of analysts rating it a buy and a consensus price target of $201.50, the stock offers upside potential, but investors should monitor debt levels and macroeconomic pressures on energy demand.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
